用于治疗性蛋白质和递送的聚合体:朝着更好的载荷特性
1Ministry of Educational (MOE) Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, People's Republic of China.
International journal of nanomedicine
|March 13, 2024
概括
聚合体为增强治疗性蛋白质和的输送提供了一个有前途的解决方案. 新的方法和分子间相互作用显著提高了它们的负载能力,以获得更好的药物配方.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 治疗性蛋白质和对于治疗糖尿病和癌症等疾病至关重要.
- 它们的临床实用性受到短半衰期和低生物利用度的限制.
- 聚合体正在成为多功能载体来克服这些局限性.
研究的目的:
- 审查聚合体在治疗性蛋白质和交付方面的潜力.
- 突出用于提高聚合物体封装效率的新方法.
- 讨论提高生物宏分子负载含量的策略.
主要方法:
- 概述了用于蛋白质和类封装的聚合体配方的最新进展.
- 分析利用分子间相互作用 (静电,脂蛋白,水) 来增强负荷的策略.
- 探索超越传统方法的创新制备技术.
主要成果:
- 分子间相互作用显著增加了蛋白质和的加载到聚合体.
- 经过修改的传统和新的制备方法实现了令人满意的封装能力.
- 聚合体显示出治疗性生物大分子的高含量负载的潜力.
结论:
- 聚合酶体代表了治疗性蛋白质和的下一代载体系统.
- 通过定制的分子间相互作用和先进的制备方法,可以实现负载内容的优化.
- 这种方法对开发改进的药物配方产品充满希望.
相关概念视频
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160


